Jeroen C J Eikenboom

List of Publications by Citations

229 papers	8,977 citations	50 h-index	89 g-index
242 ext. papers	10,377 ext. citations	7.5 avg, IF	5.89 L-index

#	Paper	IF	Citations
229	Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on von Willebrand Factor. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2103-14	15.4	884
228	A quantitative analysis of bleeding symptoms in type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1 VWD). *Journal of Thrombosis and Haemostasis*, **2006**, 4, 766-73	15.4	414
227	Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. *American Heart Journal*, **2007**, 154, 221-31	4.9	330
226	Phenotype and genotype of a cohort of families historically diagnosed with type 1 von Willebrand disease in the European study, Molecular and Clinical Markers for the Diagnosis and Management of Type 1 von Willebrand Disease (MCMDM-1VWD). *Blood*, **2007**, 109, 112-21	2.2	309
225	Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. *Archives of Internal Medicine*, **2007**, 167, 1593-9		305
224	The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2619-26	15.4	275
223	Von Willebrand's Disease. *New England Journal of Medicine*, **2016**, 375, 2067-2080	59.2	240
222	Elevated factor VIII levels and the risk of thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2001**, 21, 731-8	9.4	226
221	Prevalence of persistent platelet reactivity despite use of aspirin: a systematic review. *American Heart Journal*, **2007**, 153, 175-81	4.9	205
220	The value of family history as a risk indicator for venous thrombosis. *Archives of Internal Medicine*, **2009**, 169, 610-5		198
219	Functional architecture of Weibel-Palade bodies. *Blood*, **2011**, 117, 5033-43	2.2	190
218	Increased Levels of Factor VIII and Fibrinogen in Patients with Venous Thrombosis Are not Caused by Acute Phase Reactions. *Thrombosis and Haemostasis*, **1999**, 81, 680-683	7	187
217	Response to desmopressin is influenced by the genotype and phenotype in type 1 von Willebrand disease (VWD): results from the European Study MCMDM-1VWD. *Blood*, **2008**, 111, 3531-9	2.2	162
216	Principles of care for the diagnosis and treatment of von Willebrand disease. *Haematologica*, **2013**, 98, 667-74	6.6	139
215	Identification of type 1 von Willebrand disease patients with reduced von Willebrand factor survival by assay of the VWF propeptide in the European study: molecular and clinical markers for the diagnosis and management of type 1 VWD (MCMDM-1VWD). *Blood*, **2008**, 111, 4979-85	2.2	123
214	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). *Journal of Thrombosis and Haemostasis*, **2008**, 6, 762-71	15.4	116
213	A multicenter randomized study of the efficacy of transfusions with platelets stored in platelet additive solution II versus plasma. *Blood*, **2006**, 108, 3210-5	2.2	105

212	Familial Clustering of Factor VIII and von Willebrand Factor Levels. *Thrombosis and Haemostasis*, **1998**, 79, 323-327	7	102
211	Linkage analysis in families diagnosed with type 1 von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 VWD. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 774-82	15.4	100
210	Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: A different phenotype of thrombotic disease?. *Thrombosis Research*, **2020**, 193, 86-89	8.2	97
209	Platelet-dependent von Willebrand factor activity. Nomenclature and methodology: communication from the SSC of the ISTH. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1345-50	15.4	93
208	Inconsistency of Association between Type 1 von Willebrand Disease Phenotype and Genotype in Families Identified in an Epidemiological Investigation. *Thrombosis and Haemostasis*, **1999**, 82, 1065-1070	7	92
207	Prospective evaluation of the clinical utility of quantitative bleeding severity assessment in patients referred for hemostatic evaluation. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 1143-8	15.4	89
206	Characterization of the Genetic Defects in Recessive Type 1 and Type 3 von Willebrand Disease Patients of Italian Origin. *Thrombosis and Haemostasis*, **1998**, 79, 709-717	7	80
205	von Willebrand factor and its propeptide: the influence of secretion and clearance on protein levels and the risk of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2556-62	15.4	79
204	The clinical impact of platelet refractoriness: correlation with bleeding and survival. *Transfusion*, **2008**, 48, 1959-65	2.9	73
203	ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. *Blood Advances*, **2021**, 5, 280-300	7.8	72
202	Congenital von Willebrand disease type 3: clinical manifestations, pathophysiology and molecular biology. *Best Practice and Research in Clinical Haematology*, **2001**, 14, 365-79	4.2	71
201	Type 1 von Willebrand disease mutation Cys1149Arg causes intracellular retention and degradation of heterodimers: a possible general mechanism for dominant mutations of oligomeric proteins. *Blood*, **2001**, 98, 2973-9	2.2	70
200	VWF propeptide and ratios between VWF, VWF propeptide, and FVIII in the characterization of type 1 von Willebrand disease. *Blood*, **2013**, 121, 2336-9	2.2	69
199	High factor VIII antigen levels increase the risk of venous thrombosis but are not associated with polymorphisms in the von Willebrand factor and factor VIII gene. *British Journal of Haematology*, **2001**, 115, 156-8	4.5	69
198	von Willebrand disease and aging: an evolving phenotype. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 1066-75	15.4	68
197	Cysteine-mutations in von Willebrand factor associated with increased clearance. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 2228-37	15.4	66
196	Reduced prevalence of arterial thrombosis in von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 845-54	15.4	65
195	The effects of pre- and postoperative fibrinogen levels on blood loss after cardiac surgery: a systematic review and meta-analysis. *Interactive Cardiovascular and Thoracic Surgery*, **2014**, 18, 292-8	1.8	64

194	Determinants of bleeding phenotype in adult patients with moderate or severe von Willebrand disease. *Thrombosis and Haemostasis*, **2012**, 108, 683-92	7	64
193	Fibrinogen Aalpha Thr312Ala polymorphism is associated with chronic thromboembolic pulmonary hypertension. *European Respiratory Journal*, **2008**, 31, 736-41	13.6	64
192	Proteomic screen identifies IGFBP7 as a novel component of endothelial cell-specific Weibel-Palade bodies. *Journal of Proteome Research*, **2012**, 11, 2925-36	5.6	62
191	Multiple substitutions in the von Willebrand factor gene that mimic the pseudogene sequence. *Proceedings of the National Academy of Sciences of the United States of America*, **1994**, 91, 2221-4	11.5	62
190	Primary postpartum haemorrhage in women with von Willebrand disease or carriership of haemophilia despite specialised care: a retrospective survey. *Haemophilia*, **2015**, 21, 505-12	3.3	61
189	Heritability of elevated factor VIII antigen levels in factor V Leiden families with thrombophilia. *British Journal of Haematology*, **2000**, 109, 519-22	4.5	61
188	ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. *Thrombosis and Haemostasis*, **2007**, 97, 534-541	7	60
187	Variations in glycosylation of von Willebrand factor with O-linked sialylated T antigen are associated with its plasma levels. *Blood*, **2007**, 109, 2430-7	2.2	57
186	Health-related quality of life among adult patients with moderate and severe von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1492-9	15.4	54
185	Dimerization and multimerization defects of von Willebrand factor due to mutated cysteine residues. *Journal of Thrombosis and Haemostasis*, **2004**, 2, 257-65	15.4	54
184	A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism. *Thrombosis Research*, **2011**, 128, 21-6	8.2	53
183	Hemorrhagic symptoms and bleeding risk in obligatory carriers of type 3 von Willebrand disease: an international, multicenter study. *Journal of Thrombosis and Haemostasis*, **2006**, 4, 2164-9	15.4	53
182	Factor V antigen levels and venous thrombosis: risk profile, interaction with factor V leiden, and relation with factor VIII antigen levels. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2000**, 20, 1382-8	9.4	53
181	Coagulation parameters of thawed fresh-frozen plasma during storage at different temperatures. *Transfusion Medicine*, **2007**, 17, 182-6	1.3	52
180	Analysis of the storage and secretion of von Willebrand factor in blood outgrowth endothelial cells derived from patients with von Willebrand disease. *Blood*, **2013**, 121, 2762-72	2.2	51
179	von Willebrand factor propeptide and the phenotypic classification of von Willebrand disease. *Blood*, **2015**, 125, 3006-13	2.2	49
178	Gynaecological and obstetric bleeding in moderate and severe von Willebrand disease. *Thrombosis and Haemostasis*, **2011**, 106, 885-92	7	49
177	Expression of 14 von Willebrand factor mutations identified in patients with type 1 von Willebrand disease from the MCMDM-1VWD study. *Journal of Thrombosis and Haemostasis*, **2009**, 7, 1304-12	15.4	48

176	Time-dependent effects of aspirin on blood pressure and morning platelet reactivity: a randomized cross-over trial. *Hypertension*, **2015**, 65, 743-50	8.5	46
175	Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial. *Thrombosis and Haemostasis*, **2014**, 112, 1209-18	7	45
174	Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD). *Journal of Thrombosis and Haemostasis*, **2007**, 5, 715-21	15.4	44
173	A patient with von Willebrand's disease characterized by a compound heterozygosity for a substitution of Arg854 by Gln in the putative factor-VIII-binding domain of von Willebrand factor (vWF) on one allele and very low levels of mRNA from the second vWF allele. *British Journal of Haematology*, **1992**, 80, 358-63	4.5	42
172	High D-dimer level is associated with increased 15-d and 3 months mortality through a more central localization of pulmonary emboli and serious comorbidity. *British Journal of Haematology*, **2008**, 140, 218-22	4.5	41
171	Developments in the diagnostic procedures for von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2016**, 14, 449-60	15.4	40
170	The Factor VIII/Von Willebrand Factor Ratio Discriminates between Reduced Synthesis and Increased Clearance of Von Willebrand Factor. *Thrombosis and Haemostasis*, **2002**, 87, 252-257	7	39
169	Mutations in Severe, Type III von Willebrand Disease in the Dutch Population: Candidate Missense and Nonsense Mutations Associated with Reduced Levels of von Willebrand Factor Messenger RNA. *Thrombosis and Haemostasis*, **1992**, 68, 448-454	7	39
168	CLEC4M and STXBP5 gene variations contribute to von Willebrand factor level variation in von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 956-66	15.4	38
167	Plasma levels of microparticle-associated tissue factor activity in patients with clinically suspected pulmonary embolism. *Thrombosis Research*, **2010**, 126, 345-9	8.2	37
166	STXBP1 promotes Weibel-Palade body exocytosis through its interaction with the Rab27A effector Slp4-a. *Blood*, **2014**, 123, 3185-94	2.2	36
165	Weibel-Palade bodies: a window to von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 581-92	15.4	36
164	Intracellular storage and regulated secretion of von Willebrand factor in quantitative von Willebrand disease. *Journal of Biological Chemistry*, **2011**, 286, 24180-8	5.4	34
163	Comparison of CT assessed right ventricular size and cardiac biomarkers for predicting short-term clinical outcome in normotensive patients suspected of having acute pulmonary embolism. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 853-6	15.4	34
162	Autosomal dominant type 1 von willebrand disease due to G3639T mutation (C1130F) in exon 26 of von Willebrand factor gene: description of five Italian families and evidence for a founder effect. *British Journal of Haematology*, **2000**, 108, 876-9	4.5	34
161	The impact of bleeding history, von Willebrand factor and PFA-100( ) on the diagnosis of type 1 von Willebrand disease: results from the European study MCMDM-1VWD. *British Journal of Haematology*, **2010**, 151, 245-51	4.5	32
160	Value of multidisciplinary reassessment in attribution of neuropsychiatric events to systemic lupus erythematosus: prospective data from the Leiden NPSLE cohort. *Rheumatology*, **2017**, 56, 1676-1683	3.9	30
159	Von Willebrand disease mutation spectrum and associated mutation mechanisms. *Thrombosis Research*, **2017**, 159, 65-75	8.2	30

158	Immunoglobulin A multiple myeloma presenting with Henoch-Schönlein purpura associated with reduced sialylation of IgA1. *British Journal of Haematology*, **2003**, 122, 915-7	4.5	30
157	The minor allele of GP6 T13254C is associated with decreased platelet activation and a reduced risk of recurrent cardiovascular events and mortality: results from the SMILE-Platelets project. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2377-84	15.4	29
156	Acquired von Willebrand's disease due to excessive fibrinolysis. *British Journal of Haematology*, **1992**, 81, 618-20	4.5	29
155	Joint bleeds in von Willebrand disease patients have significant impact on quality of life and joint integrity: a cross-sectional study. *Haemophilia*, **2015**, 21, e185-92	3.3	27
154	Biogenesis of Weibel-Palade bodies in von Willebrand's disease variants with impaired von Willebrand factor intrachain or interchain disulfide bond formation. *Haematologica*, **2012**, 97, 859-66	6.6	27
153	Comorbidities associated with higher von Willebrand factor (VWF) levels may explain the age-related increase of VWF in von Willebrand disease. *British Journal of Haematology*, **2018**, 182, 93-105	4.5	27
152	von Willebrand factor remodeling during exocytosis from vascular endothelial cells. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 2009-19	15.4	26
151	Cohort Study on the Management of Cancer-Associated Venous Thromboembolism Aimed at the Safety of Stopping Anticoagulant Therapy in Patients Cured of Cancer. *Chest*, **2016**, 149, 1245-51	5.3	25
150	Von Willebrand's Disease. *New England Journal of Medicine*, **2017**, 376, 701-2	59.2	23
149	Angiogenic characteristics of blood outgrowth endothelial cells from patients with von Willebrand disease. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 1854-66	15.4	23
148	ABO blood group genotypes, plasma von Willebrand factor levels and loading of von Willebrand factor with A and B antigens. *Thrombosis and Haemostasis*, **2007**, 97, 534-41	7	23
147	Diagnosis and management of von Willebrand disease in The Netherlands. *Seminars in Thrombosis and Hemostasis*, **2011**, 37, 480-7	5.3	22
146	Standardization of methods to quantify and culture endothelial colony-forming cells derived from peripheral blood: Position paper from the International Society on Thrombosis and Haemostasis SSC. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1190-1194	15.4	21
145	Comparison of thromboelastometry by ROTEM Delta and ROTEM Sigma in women with postpartum haemorrhage. *Scandinavian Journal of Clinical and Laboratory Investigation*, **2019**, 79, 32-38	2	21
144	Impact of von Willebrand disease on health-related quality of life in a pediatric population. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 502-9	15.4	21
143	Validation of a rapid test (VWF-LIA) for the quantitative determination of von Willebrand factor antigen in type 1 von Willebrand disease diagnosis within the European multicenter study MCMDM-1VWD. *Thrombosis Research*, **2010**, 126, 227-31	8.2	21
142	Acquired von Willebrand syndrome: diagnostic problems and therapeutic options. *American Journal of Hematology*, **2007**, 82, 55-8	7.1	21
141	Plasma coagulation factor levels in venous thrombosis. *Seminars in Hematology*, **2007**, 44, 77-84	4	21

140	An international survey to inform priorities for new guidelines on von Willebrand disease. *Haemophilia*, **2020**, 26, 106-116	3.3	20
139	Coagulation parameters during the course of severe postpartum hemorrhage: a nationwide retrospective cohort study. *Blood Advances*, **2018**, 2, 2433-2442	7.8	20
138	Analysis of current perioperative management with Haemate P/Humate P in von Willebrand disease: Identifying the need for personalized treatment. *Haemophilia*, **2018**, 24, 460-470	3.3	19
137	ABO blood group also influences the von Willebrand factor (VWF) antigen level in heterozygous carriers of VWF null alleles, type 2N mutation Arg854Gln, and the missense mutation Cys2362Phe. *Blood*, **2002**, 100, 1927-8	2.2	19
136	Genome-wide linkage scan in affected sibling pairs identifies novel susceptibility region for venous thromboembolism: Genetics In Familial Thrombosis study. *Journal of Thrombosis and Haemostasis*, **2013**, 11, 1474-84	15.4	18
135	Factor VIII alters tubular organization and functional properties of von Willebrand factor stored in Weibel-Palade bodies. *Blood*, **2011**, 118, 5947-56	2.2	18
134	Homozygous C2362F von Willebrand factor induces intracellular retention of mutant von Willebrand factor resulting in autosomal recessive severe von Willebrand disease. *British Journal of Haematology*, **2006**, 133, 409-18	4.5	18
133	Efficacy, safety and user-friendliness of two devices for postoperative autologous shed red blood cell re-infusion in elective orthopaedic surgery patients: A randomized pilot study. *Transfusion Medicine*, **2006**, 16, 321-8	1.3	18
132	Clinically relevant differences between assays for von Willebrand factor activity. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 2413-2424	15.4	18
131	The effect of tranexamic acid on blood loss and maternal outcome in the treatment of persistent postpartum hemorrhage: A nationwide retrospective cohort study. *PLoS ONE*, **2017**, 12, e0187555	3.7	17
130	von Willebrand factor variant p.Arg924Gln marks an allele associated with reduced von Willebrand factor and factor VIII levels. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1986-93	15.4	17
129	Differential effects of the loss of intrachain- versus interchain-disulfide bonds in the cystine-knot domain of von Willebrand factor on the clinical phenotype of von Willebrand disease. *Thrombosis and Haemostasis*, **2006**, 96, 717-24	7	17
128	Compliance with prophylactic platelet transfusion trigger in haematological patients. *Transfusion Medicine*, **2005**, 15, 45-8	1.3	17
127	An evidence-based approach to pre-pregnancy counselling for patients with systemic lupus erythematosus. *Rheumatology*, **2018**, 57, 1707-1720	3.9	17
126	Instability of repeats of the von Willebrand factor gene variable number tandem repeat sequence in intron 40. *British Journal of Haematology*, **1993**, 84, 533-5	4.5	16
125	State of the art: von Willebrand disease. *Haemophilia*, **2016**, 22 Suppl 5, 54-9	3.3	16
124	Mortality, life expectancy, and causes of death of persons with hemophilia in the Netherlands 2001-2018. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 645-653	15.4	16
123	No evidence for a direct effect of von Willebrand factor's ABH blood group antigens on von Willebrand factor clearance. *Journal of Thrombosis and Haemostasis*, **2015**, 13, 592-600	15.4	15

122	Hemostatic alterations during coronary artery bypass grafting. *Thrombosis Research*, **2016**, 140, 140-146	8.2	15
121	Haplotypes encoding the factor VIII 1241 Glu variation, factor VIII levels and the risk of venous thrombosis. *Thrombosis and Haemostasis*, **2006**, 95, 942-8	7	15
120	Maternal and neonatal bleeding complications in relation to peripartum management in women with Von Willebrand disease: A systematic review. *Blood Reviews*, **2020**, 39, 100633	11.1	15
119	Long-term impact of joint bleeds in von Willebrand disease: a nested case-control study. *Haematologica*, **2017**, 102, 1486-1493	6.6	14
118	Recurrence risk after anticoagulant treatment of limited duration for late, second venous thromboembolism. *Haematologica*, **2015**, 100, 188-93	6.6	14
117	Phosphatidylinositol-3,4,5-triphosphate-dependent Rac exchange factor 1 regulates epinephrine-induced exocytosis of Weibel-Palade bodies. *Journal of Thrombosis and Haemostasis*, **2014**, 12, 273-81	15.4	14
116	Beta 2 adrenergic receptor polymorphisms: association with factor VIII and von Willebrand factor levels and the risk of venous thrombosis. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 405-7	15.4	14
115	A novel candidate mutation (Arg611-->His) in type I 'platelet discordant' von Willebrand's disease with desmopressin-induced thrombocytopenia. *British Journal of Haematology*, **1995**, 89, 656-8	4.5	14
114	Content delivery to newly forming Weibel-Palade bodies is facilitated by multiple connections with the Golgi apparatus. *Blood*, **2015**, 125, 3509-16	2.2	13
113	Polymorphic variation within the VWF gene contributes to the failure to detect mutations in patients historically diagnosed with type 1 von Willebrand disease from the MCMDM-1VWD cohort. *Haematologica*, **2010**, 95, 2163-5	6.6	13
112	High levels of low-density lipoprotein cholesterol and triglycerides and suboptimal glycemic control predict diminished ex vivo aspirin responsiveness in patients with Type 2 diabetes. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 1562-4	15.4	13
111	Mutational analysis of the von Willebrand factor gene in type 1 von Willebrand disease using conformation sensitive gel electrophoresis: a comparison of fluorescent and manual techniques. *Haematologica*, **2007**, 92, 550-3	6.6	13
110	Health-related quality of life, developmental milestones, and self-esteem in young adults with bleeding disorders. *Quality of Life Research*, **2018**, 27, 159-171	3.7	12
109	A novel family with recessive von Willebrand disease due to compound heterozygosity for a splice site mutation and a missense mutation in the von Willebrand factor gene. *Thrombosis Research*, **2002**, 105, 135-8	8.2	12
108	Paroxysmal Finger Haematoma: A Neglected Syndrome. *Thrombosis and Haemostasis*, **1991**, 66, 266-266	7	12
107	Association between fluid management and dilutional coagulopathy in severe postpartum haemorrhage: a nationwide retrospective cohort study. *BMC Pregnancy and Childbirth*, **2018**, 18, 398	3.2	12
106	The common single nucleotide variants c.2365A>G and c.2385T>C modify VWF biosynthesis and clearance. *Blood Advances*, **2018**, 2, 1585-1594	7.8	12
105	Comparison of haemostatic function of PAS-C-platelets vs. plasma-platelets in reconstituted whole blood using impedance aggregometry and thromboelastography. *Vox Sanguinis*, **2017**, 112, 549-556	3.1	11

104	Correction of a dominant-negative von Willebrand factor multimerization defect by small interfering RNA-mediated allele-specific inhibition of mutant von Willebrand factor. *Journal of Thrombosis and Haemostasis*, **2018**, 16, 1357-1368	15.4	11
103	A comparison between two semi-quantitative bleeding scales for the diagnosis and assessment of bleeding severity in type 1 von Willebrand disease. *Haemophilia*, **2011**, 17, 165-6	3.3	11
102	Efficacy of recombinant activated Factor VII in patients with massive uncontrolled bleeding: a retrospective observational analysis. *Transfusion*, **2009**, 49, 570-7	2.9	11
101	Are serum autoantibodies associated with brain changes in systemic lupus erythematosus? MRI data from the Leiden NP-SLE cohort. *Lupus*, **2019**, 28, 94-103	2.6	11
100	Lifecycle of Weibel-Palade bodies. *Hamostaseologie*, **2017**, 37, 13-24	1.9	10
99	Formation of platelet-binding von Willebrand factor strings on non-endothelial cells. *Journal of Thrombosis and Haemostasis*, **2012**, 10, 2168-78	15.4	10
98	Value assignment of the WHO 6th International Standard for blood coagulation factor VIII and von Willebrand factor in plasma (07/316). *Journal of Thrombosis and Haemostasis*, **2011**, 9, 2100-2	15.4	10
97	Functional variation in the arginine vasopressin 2 receptor as a modifier of human plasma von Willebrand factor levels. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 1547-54	15.4	10
96	Von Willebrand disease and Weibel-Palade bodies. *Hamostaseologie*, **2010**, 30, 150-155	1.9	10
95	Flow cytometric mepacrine fluorescence can be used for the exclusion of platelet dense granule deficiency. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 706-713	15.4	10
94	The factor VIII/von Willebrand factor ratio discriminates between reduced synthesis and increased clearance of von Willebrand factor. *Thrombosis and Haemostasis*, **2002**, 87, 252-7	7	10
93	Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2145-2154	15.4	9
92	Circulating Angiogenic Mediators in Patients with Moderate and Severe von Willebrand Disease: A Multicentre Cross-Sectional Study. *Thrombosis and Haemostasis*, **2018**, 118, 152-160	7	9
91	First report of inhibitory von Willebrand factor alloantibodies in type 2B von Willebrand disease. *British Journal of Haematology*, **2015**, 171, 424-7	4.5	9
90	Effect of fibrinolysis on bleeding phenotype in moderate and severe von Willebrand disease. *Haemophilia*, **2012**, 18, 444-51	3.3	9
89	The inheritance and molecular genetics of von Willebrand's disease. *Haemophilia*, **1995**, 1, 77-90	3.3	9
88	Circulating Endothelial Markers in Retinal Vasculopathy With Cerebral Leukoencephalopathy and Systemic Manifestations. *Stroke*, **2017**, 48, 3301-3307	6.7	8
87	Heightened proteolysis of the von Willebrand factor subunit in patients with von Willebrand disease hemizygous or homozygous for the C2362F mutation. *British Journal of Haematology*, **2000**, 108, 188-90	4.5	8

86	More on clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism. *Thrombosis Research*, **2020**, 196, 435-436	8.2	8
85	Association of Timing of Plasma Transfusion With Adverse Maternal Outcomes in Women With Persistent Postpartum Hemorrhage. *JAMA Network Open*, **2019**, 2, e1915628	10.4	8
84	Incidence and Clinical Significance of Cerebral Embolism During Atrial Fibrillation Ablation With Duty-Cycled Phased-Radiofrequency Versus Cooled-Radiofrequency: A Randomized Controlled Trial. *JACC: Clinical Electrophysiology*, **2019**, 5, 318-326	4.6	7
83	BMI is an important determinant of VWF and FVIII levels and bleeding phenotype in patients with von Willebrand disease. *American Journal of Hematology*, **2019**, 94, E201-E205	7.1	7
82	Stopping antiplatelet medication before coronary artery bypass graft surgery: is there an optimal timing to minimize bleeding?. *European Journal of Cardio-thoracic Surgery*, **2015**, 48, e64-70	3	7
81	Joint assessment in von Willebrand disease. Validation of the Haemophilia Joint Health score and Haemophilia Activities List. *Thrombosis and Haemostasis*, **2017**, 117, 1465-1470	7	7
80	Towards the imaging of Weibel-Palade body biogenesis by serial block face-scanning electron microscopy. *Journal of Microscopy*, **2015**, 259, 97-104	1.9	7
79	Storage and secretion of naturally occurring von Willebrand factor A domain variants. *British Journal of Haematology*, **2014**, 167, 529-40	4.5	7
78	Acute myocardial infarction during substitution with recombinant factor VIII concentrate in a patient with mild haemophilia A. *Thrombosis and Haemostasis*, **2004**, 92, 425-426	7	7
77	Higher Tinzaparin Dosing Is Needed to Achieve Target Anti-Xa Levels in Pediatric Cardiac Intensive Care Patients. *Pediatric Critical Care Medicine*, **2016**, 17, 203-9	3	7
76	Sports participation and physical activity in patients with von Willebrand disease. *Haemophilia*, **2019**, 25, 101-108	3.3	7
75	Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2687-2701	15.4	7
74	Anticoagulant treatment and bleeding complications in patients with left ventricular assist devices. *Expert Review of Cardiovascular Therapy*, **2020**, 18, 363-372	2.5	6
73	Lowering the increased intracellular pH of human-induced pluripotent stem cell-derived endothelial cells induces formation of mature Weibel-Palade bodies. *Stem Cells Translational Medicine*, **2020**, 9, 758-772	6.9	6
72	Variability of von Willebrand factor-related parameters in endothelial colony forming cells. *Journal of Thrombosis and Haemostasis*, **2019**, 17, 1544-1554	15.4	6
71	Blood group significantly influences von Willebrand factor increase and half-life after desmopressin in von Willebrand disease Vicenza. *Journal of Thrombosis and Haemostasis*, **2010**, 8, 2078-80	15.4	6
70	Autosomal recessive von Willebrand disease associated with compound heterozygosity for a novel nonsense mutation (2908 del C) and the missense mutation C2362F: definite evidence for the non-penetrance of the C2362F mutation. *American Journal of Hematology*, **2007**, 82, 376-80	7.1	6
69	Peri-Operative Replacement Therapy with Factor VII Concentrate in a Patient with Severe Factor VII Deficiency. *Thrombosis and Haemostasis*, **1992**, 67, 285-286	7	6

68	Fatigue in patients with systemic lupus erythematosus and neuropsychiatric symptoms is associated with anxiety and depression rather than inflammatory disease activity. *Lupus*, **2021**, 30, 1124-1132	2.6	6
67	von Willebrand factor and factor VIII levels after desmopressin are associated with bleeding phenotype in type 1 VWD. *Blood Advances*, **2019**, 3, 4147-4154	7.8	6
66	Home treatment of patients with cancer-associated venous thromboembolism - An evaluation of daily practice. *Thrombosis Research*, **2019**, 184, 122-128	8.2	6
65	Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study. *American Journal of Hematology*, **2021**, 96, 51-59	7.1	6
64	Rise of levels of von Willebrand factor and factor VIII with age: Role of genetic and acquired risk factors. *Thrombosis Research*, **2021**, 197, 172-178	8.2	6
63	Long-Term Outcome after Joint Bleeds in Von Willebrand Disease Compared to Haemophilia A: A Post Hoc Analysis. *Thrombosis and Haemostasis*, **2018**, 118, 1690-1700	7	6
62	Von Willebrand disease and Weibel-Palade bodies. *Hamostaseologie*, **2010**, 30, 150-5	1.9	6
61	Plasma levels of plasminogen activator inhibitor-1 and bleeding phenotype in patients with von Willebrand disease. *Haemophilia*, **2017**, 23, 437-443	3.3	5
60	Correlative light microscopy and electron tomography to study Von Willebrand factor exocytosis from vascular endothelial cells. *Methods in Cell Biology*, **2014**, 124, 71-92	1.8	5
59	Haplotypes encoding the factor VIII 1241Glu variation and the risk of myocardial infarction. *Journal of Thrombosis and Haemostasis*, **2007**, 5, 619-21	15.4	5
58	Identification and Characterization of Novel Variations in Platelet G-Protein Coupled Receptor (GPCR) Genes in Patients Historically Diagnosed with Type 1 von Willebrand Disease. *PLoS ONE*, **2015**, 10, e0143913	3.7	5
57	Mortality in patients with systemic lupus erythematosus and neuropsychiatric involvement: A retrospective analysis from a tertiary referral center in the Netherlands. *Lupus*, **2020**, 29, 1892-1901	2.6	5
56	Ex vivo Improvement of a von Willebrand Disease Type 2A Phenotype Using an Allele-Specific Small-Interfering RNA. *Thrombosis and Haemostasis*, **2020**, 120, 1569-1579	7	5
55	Clinical value of early viscoelastometric point-of-care testing during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. *Acta Obstetricia Et Gynecologica Scandinavica*, **2021**, 100, 1656-1664	3.8	5
54	Association between micro particle-tissue factor activity, factor VIII activity and recurrent VTE in patients with acute pulmonary embolism. *Journal of Thrombosis and Thrombolysis*, **2015**, 40, 323-30	5.1	4
53	von Willebrand disease biology. *Haemophilia*, **2012**, 18 Suppl 4, 141-7	3.3	4
52	Effect of the VWF promoter (GT)n repeat and single-nucleotide polymorphism c.-2527G>A on circulating von Willebrand factor levels under normal conditions. *Journal of Thrombosis and Haemostasis*, **2011**, 9, 603-5	15.4	4
51	Evaluation of the von Willebrand factor Y1584C polymorphism as a potential risk factor for bleeding in patients receiving anticoagulant treatment with vitamin K antagonists. *Journal of Thrombosis and Haemostasis*, **2005**, 3, 797-8	15.4	4

50	Grossly Abnormal Proteolysis of von Willebrand Factor (VWF) in a Patient Heterozygous for a Gene Deletion and Mutation in the Dimerization Area of VWF. *Thrombosis and Haemostasis*, **2000**, 84, 729-730	7	4
49	von Willebrand disease: proposing definitions for future research. *Blood Advances*, **2021**, 5, 565-569	7.8	4
48	One piece of the puzzle: Population pharmacokinetics of FVIII during perioperative Haemate P /Humate P treatment in von Willebrand disease patients. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 295-305	15.4	4
47	The prevalence and burden of hand and wrist bleeds in von Willebrand disease. *Haemophilia*, **2019**, 25, e35-e38	3.3	4
46	Clinical, Laboratory, and Molecular Markers of Type 3 von Willebrand Disease148-165		4
45	Predictive value of a bleeding score for postpartum hemorrhage. *Research and Practice in Thrombosis and Haemostasis*, **2019**, 3, 277-284	5.1	3
44	Professional functioning of young adults with congenital coagulation disorders in the Netherlands. *Haemophilia*, **2019**, 25, e138-e145	3.3	3
43	Bleeding phenotype and diagnostic characterization of patients with congenital platelet defects. *American Journal of Hematology*, **2020**, 95, 1142	7.1	3
42	Congenital platelet disorders and health status-related quality of life. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 100-105	5.1	3
41	Plasma levels of von Willebrand factor, von Willebrand factor propeptide and factor VIII in carriers and patients with nephrogenic diabetes insipidus. *Thrombosis Research*, **2010**, 125, 554-6	8.2	3
40	Aquaporin 2 gene variations, risk of venous thrombosis and plasma levels of von Willebrand factor and factor VIII. *Haematologica*, **2008**, 93, 959-60	6.6	3
39	No Association Between Normalization of VWF Levels and Bleeding Phenotype in Patients with Type 1 VWD - from the Win Study. *Blood*, **2016**, 128, 2577-2577	2.2	3
38	The limitation of genetic testing in diagnosing patients suspected for congenital platelet defects. *American Journal of Hematology*, **2020**, 95, E26-E28	7.1	3
37	The association between haemorrhage and markers of endothelial insufficiency and inflammation in patients with hypoproliferative thrombocytopenia: a cohort study. *British Journal of Haematology*, **2020**, 189, 171-181	4.5	3
36	Endothelial characteristics in healthy endothelial colony forming cells; generating a robust and valid ex vivo model for vascular disease. *Journal of Thrombosis and Haemostasis*, **2020**, 18, 2721-2731	15.4	3
35	Health and treatment outcomes of patients with hemophilia in the Netherlands, 1972-2019. *Journal of Thrombosis and Haemostasis*, **2021**, 19, 2394-2406	15.4	3
34	Maternal and neonatal bleeding complications in relation to peripartum management in hemophilia carriers: A systematic review. *Blood Reviews*, **2021**, 49, 100826	11.1	3
33	von Willebrand Factor and Factor VIII Clearance in Perioperative Hemophilia A Patients. *Thrombosis and Haemostasis*, **2020**, 120, 1056-1065	7	2

32	Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in Daily Practice. *TH Open*, **2020**, 4, e119-e126	2.7	2
31	Characterization of large in-frame von Willebrand factor deletions highlights differing pathogenic mechanisms. *Blood Advances*, **2020**, 4, 2979-2990	7.8	2
30	Joint surgery in von Willebrand disease: a multicentre cross-sectional study. *Haemophilia*, **2016**, 22, 256-262	3.5	2
29	The use of rituximab therapy in patients with acquired factor V inhibitors. *American Journal of Hematology*, **2012**, 87, 826-7	7.1	2
28	Is a V/Q scan based algorithm correctly used to diagnose acute pulmonary embolism? A daily practice survey. *Thrombosis Research*, **2011**, 128, 221-6	8.2	2
27	Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD): reply to a rebuttal. *Journal of Thrombosis and Haemostasis*,	15.4	2
26	Prevalence, burden and treatment effects of vaginal bleeding in women with (suspected) congenital platelet disorders throughout life: a cross-sectional study. *British Journal of Haematology*, **2021**,	4.5	2
25	Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction. *Haemophilia*, **2021**, 27, 581-590	3.3	2
24	ADAMTS-13 and bleeding phenotype in von Willebrand disease. *Research and Practice in Thrombosis and Haemostasis*, **2020**, 4, 1331-1339	5.1	1
23	P807Asymptomatic cerebral embolism in ablation with the second generation PVAC Gold. *European Heart Journal*, **2017**, 38,	9.5	1
22	Clinical value of early assessment of hyperfibrinolysis by rotational thromboelastometry during postpartum hemorrhage for the prediction of severity of bleeding: A multicenter prospective cohort study in the Netherlands. *Acta Obstetricia Et Gynecologica Scandinavica*, **2021**, 101, 145	3.8	1
21	Hepatitis C virus in hemophilia: Health-related quality of life after successful treatment in the sixth Hemophilia in the Netherlands study. *Research and Practice in Thrombosis and Haemostasis*, **2021**, 5, e12616	5.1	1
20	Effectiveness of a multidisciplinary clinical pathway for women with systemic lupus erythematosus and/or antiphospholipid syndrome. *Lupus Science and Medicine*, **2021**, 8,	4.6	1
19	Similar sports participation as the general population in Dutch persons with haemophilia; results from a nationwide study. *Haemophilia*, **2021**, 27, 876-885	3.3	1
18	Von Willebrand Disease: From In Vivo to In Vitro Disease Models. *HemaSphere*, **2019**, 3, e297	0.3	1
17	Population pharmacokinetics of the von Willebrand factor-factor VIII interaction in patients with von Willebrand disease. *Blood Advances*, **2021**, 5, 1513-1522	7.8	0
16	Von Willebrand Factor Multimer Densitometric Analysis: Validation of the Clinical Accuracy and Clinical Implications in Von Willebrand Disease. *HemaSphere*, **2021**, 5, e542	0.3	0
15	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. *Blood Advances*, **2021**, 5, 2987-3001	7.8	0

14	Bleeding assessment tools in the diagnosis of VWD in adults and children: a systematic review and meta-analysis of test accuracy. *Blood Advances*, **2021**, 5, 5023-5031	7.8	0
13	Measuring anxiety and depression in young adult men with haemophilia using PROMIS.. *Haemophilia*, **2022**,	3.3	0
12	Importance of Genotyping in von Willebrand Disease to Elucidate Pathogenic Mechanisms and Variability in Phenotype. *HemaSphere*, **2022**, 6, e718	0.3	0
11	Separating short tandem repeat polymorphisms on microgel. *Analytical Biochemistry*, **1997**, 245, 257-9	3.1	
10	Design of a Prospective Study on Pharmacokinetic-Guided Dosing of Prophylactic Factor Replacement in Hemophilia A and B (OPTI-CLOT TARGET Study).. *TH Open*, **2022**, 6, e60-e69	2.7	
9	Unraveling a borderline antithrombin deficiency case with quantitative mass spectrometry. *Journal of Thrombosis and Haemostasis*, **2021**, 20, 145	15.4	
8	AB0430 MORTALITY IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROPSYCHIATRIC SYMPTOMS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1514.2-1514	2.4	
7	AB0383 EXTREME FATIGUE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS AND NEUROPSYCHIATRIC SYMPTOMS. *Annals of the Rheumatic Diseases*, **2020**, 79, 1491.2-1492	2.4	
6	Recurrence Risk after Limited Duration of Anticoagulant Treatment for Late Second Venous Thromboembolism. *Blood*, **2014**, 124, 591-591	2.2	
5	Investigation of the Role of Copy Number Variation In the Pathogenesis of Type 1 Von Willebrand Disease. *Blood*, **2010**, 116, 2218-2218	2.2	
4	Biogenesis and Exocytosis of Weibel-Palade Bodies Is Affected by Naturally Occurring Von Willebrand Disease Variants within the A1-A3 Domains of VWF. *Blood*, **2012**, 120, 1072-1072	2.2	
3	Illness cognitions associated with health-related quality of life in young adult men with haemophilia. *Haemophilia*, **2020**, 26, 793-799	3.3	
2	Atherothrombosis model by silencing of protein C in APOE*3-Leiden.CETP transgenic mice. *Journal of Thrombosis and Thrombolysis*, **2021**, 52, 715-719	5.1	
1	P833Comparison of the pro-coagulant state during ablation using the PVAC Gold and the Thermocool Catheter: results from the CE-AF trial. *Europace*, **2018**, 20, i154-i154	3.9	